NeoPharm CO., LTD. (092730) Fair Value & Analysis
Consumer Non-Cyclicals · KR · Market cap 300B KRW
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 21 days ago
Fair value updated Jul 20, 2026, revised from 32,327 KRW to 30,240 KRW (−6.5%) since Jul 5, 2026. Share price +22.7% over the past month.
A solid business, screening 25% undervalued on our models.
What matters now
- Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (22,680 KRW to 46,583 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 6,905 KRW – 24,100 KRW · fair‑value band 22,680 KRW – 46,583 KRW · the 24,100 KRW price screens below the 30,240 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
NeoPharm CO., LTD. (092730) currently trades at 24,100 KRW, while our model-based Fair Value estimate is 30,240 KRW, implying the stock looks roughly 25.5% undervalued today. The Quality Score stands at 67/100 (solid quality), in the Consumer Non-Cyclicals sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, NeoPharm CO., LTD. generated revenue of 86.8B KRW at a net margin of 21.0%. Revenue declined 3.2% year over year. Fundamentals as of Jul 20, 2026
Our scenario range runs from 22,680 KRW (bear case) to 46,583 KRW (bull case); at 24,100 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 80% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at 11% fair-value upside, at 25%, 092730 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (39,228 KRW) versus Asset-Based (8,368 KRW). Highest evidence: Growth DCF (80).
Notify me when 092730 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 66
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
NeoPharm CO., LTD. manufactures and sells skin care products in South Korea. The company offers Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand; products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand; body moisturizers under the Derma-B brand; and sport care …
Full company description
NeoPharm CO., LTD. manufactures and sells skin care products in South Korea. The company offers Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand; products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand; body moisturizers under the Derma-B brand; and sport care products for athletes under the MISSION ATHELETCARE brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
NeoPharm CO., LTD. reported revenue of 132B KRW in FY2025 versus 87.9B KRW in FY2021, a compound +10.7%/yr. Reported net income was 27.8B KRW in FY2025, compounding +12.0%/yr from FY2021.
Watch 092730: get an alert when its fair value changes →
Peer Group
Consumer Staples · 1622 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Personal & Household Products & Services” was too small, so the broader sector is used.)
Valuation Multiples vs Consumer Staples median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Personal & Household Products & Services stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| FB FB | 49.00 PHP | 49.03 PHP | +0% |
| JGS JGS | 25.00 PHP | 20.51 PHP | -18% |
| URC URC | 61.20 PHP | 47.86 PHP | -22% |
| PGOLD PGOLD | 39.30 PHP | 62.75 PHP | +60% |
| RRHI RRHI | 38.00 PHP | 43.51 PHP | +15% |
| CNPF CNPF | 32.50 PHP | 64.84 PHP | +100% |
| 540743 540743 | ₹556.65 | ₹616.73 | +11% |
| DMC DMC | 7.24 PHP | 14.48 PHP | +100% |
| DNL DNL | 3.64 PHP | 3.43 PHP | -6% |
| BCOR BCOR | 9.50 PHP | 2.72 PHP | -71% |
Compare NeoPharm CO., LTD. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
Frequently asked questions
Is NeoPharm CO., LTD. (092730) overvalued or undervalued?
What is the fair value of 092730?
What is the quality score of 092730?
What is the revenue of NeoPharm CO., LTD. (092730)?
What is the net profit margin of 092730?
Does NeoPharm CO., LTD. pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track NeoPharm CO., LTD. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.